{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:42:33Z","timestamp":1793065353268,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The study was sponsored by F. Hoffmann-La Roche Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Endocrine therapy (ET) resistance in estrogen receptor positive (ER+) advanced breast cancer is often linked to\n                    <jats:italic>ESR1<\/jats:italic>\n                    mutations, yet responses to oral selective ER degraders vary within mutant subgroups. Through a biomarker analysis of acelERA Breast Cancer (NCT04576455), we show that tumor ER transcriptional activity as well as circulating tumor DNA (ctDNA) genomics and dynamics effectively stratify response to ET, including giredestrant. We find that following first-line therapy, the ctDNA genomic landscape is diverse and influenced by CDK4\/6 inhibitor exposure. Despite this complexity, ER activity in\n                    <jats:italic>ESR1<\/jats:italic>\n                    -mutant tumors remains comparable to early breast cancer but is reduced in most non-mutant cases. This maintained ER activity is associated with giredestrant benefit. Furthermore, early ctDNA clearance identifies responding patients, and the combination of low ER activity and high ctDNA burden predicts rapid clinical progression. These findings provide a framework for personalizing future breast cancer therapies by integrating liquid biopsies with tissue-based signatures.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-70335-0","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:22:04Z","timestamp":1773325324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-3238","authenticated-orcid":false,"given":"Ann E.","family":"Collier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-4990","authenticated-orcid":false,"given":"Alejandro M.","family":"Chibly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhe","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5461-9777","authenticated-orcid":false,"given":"Lincoln W.","family":"Pasquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7189-0763","authenticated-orcid":false,"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-1157","authenticated-orcid":false,"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3231","authenticated-orcid":false,"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-8838","authenticated-orcid":false,"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-2764","authenticated-orcid":false,"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Diego","family":"P\u00e9rez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9672-6428","authenticated-orcid":false,"given":"Tharu M.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"70335_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"70335_CR2","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72, 524\u2013541 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"70335_CR3","first-page":"1","volume":"2","author":"C Metcalfe","year":"2017","unstructured":"Metcalfe, C., Friedman, L. S. & Hager, J. H. Hormone-targeted therapy and resistance. Annu. Rev. Cancer Biol. 2, 1\u201322 (2017).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"70335_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell 37, 496\u2013513 (2020).","journal-title":"Cancer Cell"},{"key":"70335_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel, R., Klein, P., Tiersten, A. & Sparano, J. A. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. npj Breast Cancer 9, 20 (2023).","journal-title":"npj Breast Cancer"},{"key":"70335_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will, M., Liang, J., Metcalfe, C. & Chandarlapaty, S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat. Rev. Cancer 23, 673\u2013685 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"70335_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.2022.40.16_suppl.589","volume":"40","author":"PA Fasching","year":"2022","unstructured":"Fasching, P. A. et al. Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor\u2013positive, HER2-negative, untreated early breast cancer (ER+\/HER2\u2013 eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. J. Clin. Oncol. 40, 589\u2013589 (2022).","journal-title":"J. Clin. Oncol."},{"key":"70335_CR8","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1200\/JCO.22.00841","volume":"40","author":"KG Sanchez","year":"2022","unstructured":"Sanchez, K. G., Nangia, J. R., Schiff, R. & Rimawi, M. F. Elacestrant and the promise of oral SERDs. J. Clin. Oncol. 40, 3227\u20133229 (2022).","journal-title":"J. Clin. Oncol."},{"key":"70335_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/13543784.2021.1983542","volume":"31","author":"Y-C Chen","year":"2022","unstructured":"Chen, Y.-C. et al. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Expert Opin. Investig. Drugs 31, 515\u2013529 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"70335_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn, R., Buchwalter, G., Angelis, C. D., Brown, M. & Schiff, R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol. 12, 573\u2013583 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70335_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00617-7","volume":"10","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary, N. et al. CDK4\/6i-treated HR+\/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ Breast Cancer 10, 15 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"70335_CR12","doi-asserted-by":"publisher","first-page":"S634","DOI":"10.1016\/j.annonc.2022.07.251","volume":"33","author":"SM Tolaney","year":"2022","unstructured":"Tolaney, S. M. et al. 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician\u2019s choice (TPC) in patients (pts) with endocrine-resistant ER\u2009+\u2009\/HER2\u2212 advanced breast cancer (aBC). Ann. Oncol. 33, S634\u2013S635 (2022).","journal-title":"Ann. Oncol."},{"key":"70335_CR13","doi-asserted-by":"publisher","first-page":"GS3-02","DOI":"10.1158\/1538-7445.SABCS22-GS3-02","volume":"83","author":"M Oliveira","year":"2023","unstructured":"Oliveira, M. et al. Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res. 83, GS3-02\u2013GS3-02 (2023).","journal-title":"Cancer Res."},{"key":"70335_CR14","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J. Clin. Oncol. 40, 3246\u20133256 (2022).","journal-title":"J. Clin. Oncol."},{"key":"70335_CR15","doi-asserted-by":"publisher","unstructured":"Mart\u00edn, M. et al. Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. J. Clin. Oncol. JCO2301500, https:\/\/doi.org\/10.1200\/jco.23.01500 (2024).","DOI":"10.1200\/jco.23.01500"},{"key":"70335_CR16","doi-asserted-by":"publisher","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","volume":"64","author":"J Liang","year":"2021","unstructured":"Liang, J. et al. GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. J. Med. Chem. 64, 11841\u201311856 (2021).","journal-title":"J. Med. Chem."},{"key":"70335_CR17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","volume":"30","author":"KL Jhaveri","year":"2023","unstructured":"Jhaveri, K. L. et al. Phase Ia\/b study of giredestrant \u00b1palbociclib and \u00b1luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced\/metastatic breast cancer. Clin. Cancer Res. 30, 754\u2013766 (2023).","journal-title":"Clin. Cancer Res."},{"key":"70335_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","volume":"178","author":"J Guan","year":"2019","unstructured":"Guan, J. et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 178, 949\u2013963.e18 (2019).","journal-title":"Cell"},{"key":"70335_CR19","doi-asserted-by":"publisher","first-page":"S633","DOI":"10.1016\/j.annonc.2022.07.250","volume":"33","author":"MM Jimenez","year":"2022","unstructured":"Jimenez, M. M. et al. 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2\u2013 locally advanced\/metastatic breast cancer (LA\/mBC): primary analysis of the phase II, randomised, open-label acelERA BC study. Ann. Oncol. 33, S633\u2013S634 (2022).","journal-title":"Ann. Oncol."},{"key":"70335_CR20","doi-asserted-by":"publisher","first-page":"100140","DOI":"10.1016\/j.jlb.2024.100140","volume":"4","author":"A Desai","year":"2024","unstructured":"Desai, A. et al. Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases. J. Liq. Biopsy 4, 100140 (2024).","journal-title":"J. Liq. Biopsy"},{"key":"70335_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1200\/JCO.2024.42.3_suppl.199","volume":"42","author":"CM Parseghian","year":"2024","unstructured":"Parseghian, C. M. et al. Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC). J. Clin. Oncol. 42, 199\u2013199 (2024).","journal-title":"J. Clin. Oncol."},{"key":"70335_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"Z-F Lim","year":"2019","unstructured":"Lim, Z.-F. & Ma, P. C. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J. Hematol. Oncol. 12, 134 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"70335_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.2024.42.4_suppl.196","volume":"42","author":"C Sweeney","year":"2024","unstructured":"Sweeney, C. et al. Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC). J. Clin. Oncol. 42, 196\u2013196 (2024).","journal-title":"J. Clin. Oncol."},{"key":"70335_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","volume":"29","author":"ZJF Assaf","year":"2023","unstructured":"Assaf, Z. J. F. et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat. Med. 29, 859\u2013868 (2023).","journal-title":"Nat. Med."},{"key":"70335_CR25","doi-asserted-by":"publisher","unstructured":"Wyatt, A. W. et al. Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group. Clin. Cancer Res. OF1\u2013OF8, https:\/\/doi.org\/10.1158\/1078-0432.ccr-24-1883 (2024).","DOI":"10.1158\/1078-0432.ccr-24-1883"},{"key":"70335_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41571-022-00712-3","volume":"20","author":"B O\u2019Leary","year":"2023","unstructured":"O\u2019Leary, B. PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching. Nat. Rev. Clin. Oncol. 20, 67\u201368 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70335_CR27","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","volume":"29","author":"B Pellini","year":"2023","unstructured":"Pellini, B. et al. Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non\u2013small cell lung cancer. Clin. Cancer Res. 29, 4596\u20134605 (2023).","journal-title":"Clin. Cancer Res."},{"key":"70335_CR28","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer. Cancer Discov. 10, 1174\u20131193 (2020).","journal-title":"Cancer Discov."},{"key":"70335_CR29","doi-asserted-by":"crossref","unstructured":"Liang, J. et al. ER\u03b1 dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer. Nat. Cancer 6, 357\u2013371 (2025).","DOI":"10.1038\/s43018-024-00898-8"},{"key":"70335_CR30","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1200\/JCO.22.02511","volume":"41","author":"JS Parker","year":"2023","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 41, 4192\u20134199 (2023).","journal-title":"J. Clin. Oncol."},{"key":"70335_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/1055-9965.EPI-13-1017","volume":"23","author":"BJ Caan","year":"2014","unstructured":"Caan, B. J. et al. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol. Prev. Biomark. 23, 725\u2013734 (2014).","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"70335_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0431-1","volume":"15","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 15, 431 (2014).","journal-title":"Genome Biol."},{"key":"70335_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","volume":"7","author":"W Toy","year":"2017","unstructured":"Toy, W. et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 7, 277\u2013287 (2017).","journal-title":"Cancer Discov."},{"key":"70335_CR34","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792","volume":"5","author":"SW Fanning","year":"2016","unstructured":"Fanning, S. W. et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. eLife 5, e12792 (2016).","journal-title":"eLife"},{"key":"70335_CR35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","volume":"28","author":"SM Tolaney","year":"2022","unstructured":"Tolaney, S. M. et al. Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant. Clin. Cancer Res. 28, 1500\u20131506 (2022).","journal-title":"Clin. Cancer Res."},{"key":"70335_CR36","doi-asserted-by":"crossref","unstructured":"Bardia, A. et al. Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Clin. Cancer Res. 32, GS1-10-GS1-10 (2026).","DOI":"10.1158\/1557-3265.SABCS25-GS1-10"},{"key":"70335_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-00775-6","volume":"39","author":"R Sadeh","year":"2021","unstructured":"Sadeh, R. et al. ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells-of-origin. Nat. Biotechnol. 39, 586\u2013598 (2021).","journal-title":"Nat. Biotechnol."},{"key":"70335_CR38","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","volume":"29","author":"SC Baca","year":"2023","unstructured":"Baca, S. C. et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat. Med. 29, 2737\u20132741 (2023).","journal-title":"Nat. Med."},{"key":"70335_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35076-w","volume":"13","author":"A-L Doebley","year":"2022","unstructured":"Doebley, A.-L. et al. A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. Nat. Commun. 13, 7475 (2022).","journal-title":"Nat. Commun."},{"key":"70335_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","volume":"40","author":"MS Esfahani","year":"2022","unstructured":"Esfahani, M. S. et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat. Biotechnol. 40, 585\u2013597 (2022).","journal-title":"Nat. Biotechnol."},{"key":"70335_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46435-0","volume":"15","author":"KE Stanley","year":"2024","unstructured":"Stanley, K. E. et al. Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology. Nat. Commun. 15, 2220 (2024).","journal-title":"Nat. Commun."},{"key":"70335_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24994-w","volume":"12","author":"D Mathios","year":"2021","unstructured":"Mathios, D. et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat. Commun. 12, 5060 (2021).","journal-title":"Nat. Commun."},{"key":"70335_CR43","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/0008-5472.CAN-22-1123","volume":"82","author":"M Sj\u00f6str\u00f6m","year":"2022","unstructured":"Sj\u00f6str\u00f6m, M. et al. The 5-hydroxymethylcytosine landscape of prostate cancer. Cancer Res. 82, OF1\u2013OF15 (2022).","journal-title":"Cancer Res."},{"key":"70335_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","volume":"42","author":"S Heeke","year":"2024","unstructured":"Heeke, S. et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42, 225\u2013237.e5 (2024).","journal-title":"Cancer Cell"},{"key":"70335_CR45","doi-asserted-by":"publisher","first-page":"100242","DOI":"10.1016\/j.jlb.2024.100242","volume":"5","author":"B Pellini","year":"2024","unstructured":"Pellini, B. et al. Computational Variant Origin Prediction (VOP) to distinguish germline, tumor somatic, and Clonal Hematopoiesis (CH) variants in Liquid Biopsy (LBX). J. Liq. Biopsy 5, 100242 (2024).","journal-title":"J. Liq. Biopsy"},{"key":"70335_CR46","doi-asserted-by":"publisher","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse, R. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15, e0237802 (2020).","journal-title":"PLoS ONE"},{"key":"70335_CR47","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","volume":"30","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney, C. J. et al. Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 30, 4115\u20134122 (2024).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70335-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:56:38Z","timestamp":1777611398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70335-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70335"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70335-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was sponsored by F. Hoffmann-La Roche Ltd. The authors declare the following competing interests: A.E.C., S.H., A.M.C., P.D.P.-M., and H.M.M. are employees of Genentech, Inc. and hold stock in F. Hoffmann-La Roche Ltd. C.D. is an employee of Roche (China) Holding Ltd. and holds stock in F. Hoffmann-La Roche Ltd. and Bristol Myers Squibb. L.W.P. is an employee of Foundation Medicine and holds stock in Roche Holdings AG. M.CM. reports consulting fees from Novartis, AstraZeneca, and Lilly; honoraria from Exact Sciences; travel support from Novartis and AstraZeneca; advisory board participation for AstraZeneca and Roche\/Genentech; and board membership for Legacy Community Health, The Hope Foundation, and ASCO. A.B. reports grants and personal fees from Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, Daiichi Pharma\/AstraZeneca, Alyssum, and Eli Lilly. M.M. reports honoraria and advisory fees from Roche\/Genentech, Lilly, Pfizer, Novartis, Pierre Fabre, Seagen, AstraZeneca, and Daiichi-Sankyo; and research funding from Novartis, Roche, and Puma Biotechnology. E.L. reports institutional advisory\/steering committee roles and research funding from AstraZeneca, Gilead, Lilly, MSD, Novartis, Pfizer, and Roche; royalties from Walter and Eliza Hall Institute; and leadership roles at Breast Cancer Trials Australia, Garvan Institute, St Vincent\u2019s Hospital, and UNSW. J.S. reports institutional research funding from Seagen, MSD, Roche, Pfizer, Novartis, AstraZeneca, Lilly, GSK, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Qurient, Dragonfly, Eikon, Gilead, Celcuity, BMS, HLB Life Science, Sermonix, Olema, Hanmi, Ildong, and Samyang; and family stock ownership in Daiichi Sankyo. X.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3848"}}